Vitamin B12 for Malabsorption

B12 malabsorption is the one situation where oral supplementation still works surprisingly well - because a small fraction of B12 is absorbed by passive diffusion, entirely bypassing the broken machinery.

Normal absorption requires stomach acid to liberate B12 from food, intrinsic factor from gastric parietal cells to bind it, and healthy terminal ileum to take up the complex. Pernicious anaemia, atrophic gastritis, gastric or ileal resection, Crohn's disease, coeliac disease and long-term metformin or proton pump inhibitor use all interrupt this chain. Randomised trials have shown that high-dose oral B12, typically 1000-2000 micrograms daily, is as effective as intramuscular injection for correcting deficiency including in pernicious anaemia, because roughly 1 percent is absorbed passively regardless of intrinsic factor. Injections remain preferable in severe neurological disease or where adherence is uncertain.

Dietary B12 is bound to protein and released by gastric acid and pepsin, then carried by haptocorrin until pancreatic proteases transfer it to intrinsic factor in the duodenum. The intrinsic factor-B12 complex binds cubilin receptors in the terminal ileum, which is the only site of active absorption.

Each step is a failure point. Autoimmune destruction of parietal cells removes intrinsic factor; acid suppression prevents release from food while leaving supplement absorption largely intact; pancreatic insufficiency blocks transfer; ileal disease or resection removes the receptor site; metformin appears to interfere with calcium-dependent ileal uptake. The passive diffusion route absorbs about 1 percent of any oral dose independently of all of this, which is why a 1000 microgram tablet delivers roughly 10 micrograms even when the active pathway is entirely absent.

Doses here are deliberately far above the nutritional requirement to exploit passive absorption.

There are currently no studies linked to this pairing in our library, so no study list is shown.

Randomised trials and Cochrane review evidence support high-dose oral B12 as equivalent to intramuscular administration for normalising serum B12 and haematological parameters in deficiency, including malabsorptive causes. The passive diffusion mechanism is well established, and guidelines in several countries now permit oral replacement as first line in many patients. Limitations: trials are relatively small, most measure biochemical rather than neurological recovery, follow-up is often short, and there is less evidence in severe neurological presentations, where injections remain the standard. Adherence to daily lifelong tablets is also a real-world weakness that injections avoid.

B12 is water-soluble with no established upper limit and an excellent safety record even at very high doses; excess is excreted renally. Acne-like eruptions occur occasionally at high doses, and injections can cause local reactions.

Correcting severe deficiency can precipitate hypokalaemia as new red cells are produced, which warrants monitoring in profound anaemia. Neurological damage from prolonged deficiency may be only partly reversible, so delay matters - treatment should not wait for a perfect diagnostic picture when deficiency is clear.

Several very common medications are themselves the cause.

No studies are currently linked to this pairing, so no reference list is available. This section will populate as evidence is added to the library.